[go: up one dir, main page]

TR200002824T2 - TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları. - Google Patents

TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları.

Info

Publication number
TR200002824T2
TR200002824T2 TR2000/02824T TR200002824T TR200002824T2 TR 200002824 T2 TR200002824 T2 TR 200002824T2 TR 2000/02824 T TR2000/02824 T TR 2000/02824T TR 200002824 T TR200002824 T TR 200002824T TR 200002824 T2 TR200002824 T2 TR 200002824T2
Authority
TR
Turkey
Prior art keywords
flint
mflint
advanced
opg3
polypeptides
Prior art date
Application number
TR2000/02824T
Other languages
English (en)
Inventor
Frank Bumol Thomas
Dou Shenshen
Lawrence Glasebrook Andrew
Elliot Gould Kenneth
Edward Hale John
Georg Heuer Josef
Yuk Hui Kwan
Kharitonenkov Alexei
Mizrahi Jacques
Na Songqing
Wayne Noblitt Timothy
Arthur Reidy Charles
Yeong Song Ho
Wang Jian
Wu Xiying
Harold Zuckerman Steven
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200002824T2 publication Critical patent/TR200002824T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Gelismis FLINT proteini (mFLINT) FasL ve LIGHT'ye baglanir ve FasL-Fas etkilesimini önler. mFLINT FasL-Fas vasitasiyla ortaya çikan apoptotik ve pro-enflamatuvar etkinligi önler ve anormal apoptoz ve enflamasyon ile iliskilendirilen bozukluklarin tedavisinde faydalidir. Bulus FLINT ve yetiskin FLINT'e ait olan amino asitleri ve nükleotid dizilerini tedarik etmistir. FLINT ifade eden transjenik hayvanlarin hazirlanmasi ve hususiyetleri ve ayrica mFLINT kullanilan, tedaviye yönelik bilesimler ve tedavi yöntemleri de ayrica bulus içinde kapsanmistir.
TR2000/02824T 1998-03-30 1999-03-30 TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları. TR200002824T2 (tr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7985698P 1998-03-30 1998-03-30
US8607498P 1998-05-20 1998-05-20
US9964398P 1998-09-09 1998-09-09
US11257798P 1998-12-17 1998-12-17
US11270398P 1998-12-18 1998-12-18
US11293398P 1998-12-18 1998-12-18
US11340798P 1998-12-22 1998-12-22

Publications (1)

Publication Number Publication Date
TR200002824T2 true TR200002824T2 (tr) 2000-12-21

Family

ID=27568394

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02824T TR200002824T2 (tr) 1998-03-30 1999-03-30 TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları.

Country Status (16)

Country Link
US (1) US20040167074A1 (tr)
JP (1) JP2002512006A (tr)
KR (1) KR20010042364A (tr)
CN (1) CN1303429A (tr)
AU (1) AU3369199A (tr)
BR (1) BR9909328A (tr)
CA (1) CA2324517A1 (tr)
CZ (1) CZ20003433A3 (tr)
EA (1) EA200001004A1 (tr)
HU (1) HUP0102067A2 (tr)
ID (1) ID27820A (tr)
IL (1) IL138626A0 (tr)
NO (1) NO20004873L (tr)
PL (1) PL343847A1 (tr)
TR (1) TR200002824T2 (tr)
WO (1) WO1999050413A2 (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000070174A (ko) 1997-01-14 2000-11-25 벤슨 로버트 에이치. 종양 괴사 인자 수용체 6α 및 6β
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
DK1015587T3 (da) 1997-09-18 2008-08-25 Genentech Inc DcR3 polypeptid, en TNFR-homolog
CA2358508A1 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company Therapeutic applications of flint polypeptides
DE60036199T2 (de) * 1999-03-30 2008-05-21 Eli Lilly And Co., Indianapolis Proteaseresistente flint-analoge
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
JP2003506088A (ja) 1999-08-04 2003-02-18 アムジェン インコーポレーテッド ＴＮＦリガンドスーパー遺伝子ファミリーの新規のメンバーであるＦｈｍ
WO2001018041A2 (en) * 1999-09-10 2001-03-15 Eli Lilly And Company Flint proteins and formulations thereof
AU1189101A (en) * 1999-10-20 2001-04-30 Eli Lilly And Company Therapeutic applications of flint polypeptides
AU1915201A (en) * 1999-12-07 2001-06-18 Eli Lilly And Company Improving stability of flint through o-linked glycosylation
WO2002018622A2 (en) * 2000-08-25 2002-03-07 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
CA2439193A1 (en) * 2001-02-23 2002-08-29 Hideki Matsui Casoase 3 inhibitors
CA2520138C (en) 2003-03-26 2017-05-23 Apogenix Gmbh Improved fc fusion proteins
WO2006072137A1 (en) * 2005-01-07 2006-07-13 Northern Sydney And Central Coast Area Health Service Treatment for autoimmune and inflammatory conditions
DK2428252T3 (en) 2006-12-28 2015-02-16 Deutsches Krebsforsch Neutralization of the effect of CD95 to block the invasion of glioblastoma cells in vivo
EP2318441A2 (en) * 2008-07-14 2011-05-11 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
CN102671186B (zh) * 2011-09-19 2014-08-06 上海市肿瘤研究所 促造血的药物组合物及其应用
ES2589134T3 (es) 2012-07-18 2016-11-10 Apogenix Ag Inhibidores de la ruta de señalización de CD95 para el tratamiento de MDS
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
CN108463236A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗放射性和化学性损伤的方法
EP3395355A4 (en) 2015-12-18 2019-06-12 Talengen International Limited METHOD FOR PREVENTING AND TREATING ZERVIXEROSINE
JP7760374B2 (ja) 2019-03-29 2025-10-27 ターンストーン バイオロジクス コーポレイション Ｔ細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法
EP4065229A1 (en) 2019-11-27 2022-10-05 Myst Therapeutics, LLC Method of producing tumor-reactive t cell composition using modulatory agents
AU2021226903A1 (en) 2020-02-27 2022-10-20 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive T cells and related compositions thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000070174A (ko) * 1997-01-14 2000-11-25 벤슨 로버트 에이치. 종양 괴사 인자 수용체 6α 및 6β
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
WO1999004001A1 (en) * 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
JP2001512667A (ja) * 1997-08-06 2001-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトオーファンレセプターｎｔｒ−１
DK1015587T3 (da) * 1997-09-18 2008-08-25 Genentech Inc DcR3 polypeptid, en TNFR-homolog
WO1999026977A1 (en) * 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2

Also Published As

Publication number Publication date
HUP0102067A2 (hu) 2001-10-28
ID27820A (id) 2001-04-26
NO20004873D0 (no) 2000-09-28
JP2002512006A (ja) 2002-04-23
CZ20003433A3 (cs) 2001-10-17
CN1303429A (zh) 2001-07-11
IL138626A0 (en) 2001-10-31
NO20004873L (no) 2000-11-24
BR9909328A (pt) 2000-12-12
EA200001004A1 (ru) 2001-06-25
WO1999050413A2 (en) 1999-10-07
PL343847A1 (en) 2001-09-10
WO1999050413A3 (en) 1999-12-02
US20040167074A1 (en) 2004-08-26
AU3369199A (en) 1999-10-18
CA2324517A1 (en) 1999-10-07
KR20010042364A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
TR200002824T2 (tr) TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları.
US12152060B2 (en) Interleukin-2 variants and methods of uses thereof
KR101013401B1 (ko) 신규 시토카인 ｚｃｙｔｏｒ17 리간드
ES2281126T3 (es) Receptor 5 que contiene un dominio de muerte.
AU2020292421B2 (en) Novel interleukin-2 variants and bifunctional fusion molecules thereof
Götz et al. Neurotrophin-6 is a new member of the nerve growth factor family
ES2284199T3 (es) Receptor 4 que contiene dominio de muerte (dr4:receptor 4 de muerte), miembro de la superfamilia de receptores tnf y union a trail (apo-2l).
ES2287950T3 (es) Proteina receptora designada 2f1.
PT1132403E (pt) Peptidos inibidores de tgf g beta1
TR200003113T2 (tr) 3-(amino- veya aminoalkil) piridinon türevleri ve bunların HIV bağımlı hastalıkların tedavisinde kullanılması.
DE60028830D1 (de) Anti-april antikörper und hybridomazellen
DK1260521T3 (da) Immunoglobulinvarianter af specifikke Fc-epsilonreceptorer
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
MA31040B1 (fr) Anticorps anti-cd20 avec une augmentation de l'affinite de fixation sur le recepteur fc et de la fonction effectrice.
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
BR9810701A (pt) Proteìna "swollenina" de trichoderma reesei e seqâências de codificação de dna
ATE500328T1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
NO991926L (no) Oppl°selige lymfotoksin-<beta> reseptorer, anti-lymfotoksin-reseptor antistoff samt anti-lymfotoksin-ligand antistoff som terapeutiske midler til behandling av immunologiske sykdommer
ES2252786T3 (es) Muteinas de interleucina-4 de alta afinidad.
TR200000610T2 (tr) IL-8 reseptör karşıtları.
EP1456239A4 (en) HYBRID PROTEINS FACED WITH HEPARANSULFATE PROTEOGLYCANE WITH NEUREGULIN-HEPARIN BINDING DOMAIN
ATE356207T1 (de) Humanes btrcp protein
DE69922936D1 (de) Verwendung von indol-2,3-dione-3-oximderivate als ampa-antagonisten
TR200102655T2 (tr) Dört L. infantum proteininin antijen belirleyicilerini kodlayan kimerik gen.
DE69831223D1 (de) Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52